Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib + Capecitabine in Solid Tumors and HER2+ Breast Cancer
NCT00741260Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Dec 2008
- Primary completion
- Nov 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 11
01
Overview
Phase 2, open-label trial of neratinib in breast cancer and solid tumor (7 arms), sponsored by Puma Biotechnology, Inc. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 21 days, Maximum Tolerated Dose of Neratinib at 21 days and 1 more. Started Dec 2008; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT00741260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00741260.